Assessing the antitumor effects of metformin on ovarian clear cell carcinoma
Human Cell · 2024
DOI: 10.1007/s13577-024-01116-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Cell, 2024. Verfasst von Satoshi Takemori und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. Hauptthemen laut MEDLINE: Metformin, Ovarian Neoplasms, Cisplatin, Apoptosis. Die Arbeit nennt 44 Literaturangaben. Gefördert von: 2022 Grants-in-Aid for Scientific Research (Academic Research Grants)" Grant-in-Aid for Scientific Research(C) (FY2022-FY2024), 2022 Grants-in-Aid for Scientific Research (Academic Research Grants)” Grant-in-Aid for Scientific Research(C).
Abstract (Originalsprache)
Developing novel therapies that outperform the existing chemotherapeutic treatments is required for treatment-resistant ovarian clear cell carcinoma. We investigated the antitumor effect of metformin on ovarian clear cell carcinoma, enhancement of the antitumor effect by its combination with chemotherapy, and its molecular regulatory mechanism. First, we evaluated the viability of ovarian clear cell carcinoma lines using the water-soluble tetrazolium-1 assay and found that metformin suppressed cell viability. Cell viability was significantly suppressed by co-treatment with cisplatin and metformin. In contrast, co-treatment with paclitaxel and metformin showed no significant difference in viability compared with the group without metformin. Western blot analysis showed increased phosphorylation of AMP-activated protein kinase in some cell lines and suppressed phosphorylation of the mammalian target of rapamycin in a particular cell line. Flow cytometry analysis revealed a significant increase in the rate of apoptosis in the metformin-treated group and rate of cell cycle arrest at the G2/M phase in a particular cell line. These results indicated that metformin may be effective against cultured ovarian clear cell carcinoma cells, particularly in combination with cisplatin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Kyorin University, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan. tohru-morisada@ks.kyorin-u.ac.jp.
Förderung
- 2022 Grants-in-Aid for Scientific Research (Academic Research Grants)" Grant-in-Aid for Scientific Research(C) (FY2022-FY2024)
- 2022 Grants-in-Aid for Scientific Research (Academic Research Grants)” Grant-in-Aid for Scientific Research(C)
Zitieren
APA
Takemori, S., Morisada, T., Osaka, M., Watanabe, M., Tajima, A., Tanigaki, S., & Kobayashi, Y. (2024). Assessing the antitumor effects of metformin on ovarian clear cell carcinoma. Human Cell. https://doi.org/10.1007/s13577-024-01116-4
Vancouver
Takemori S, Morisada T, Osaka M, Watanabe M, Tajima A, Tanigaki S, et al. Assessing the antitumor effects of metformin on ovarian clear cell carcinoma. Human Cell. 2024. doi:10.1007/s13577-024-01116-4
BibTeX
@article{Takemori2024,
author = {Takemori, Satoshi and Morisada, Tohru and Osaka, Makoto and Watanabe, Momoe and Tajima, Atsushi and Tanigaki, Shinji and Kobayashi, Yoichi},
title = {Assessing the antitumor effects of metformin on ovarian clear cell carcinoma},
journal = {Human Cell},
year = {2024},
doi = {10.1007/s13577-024-01116-4}
}
EUVIMED